Back to search
FDAFDA · Food and drugs·Recall number D-0227-2021

Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 tablets per bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120, NDC: 29033-056-01

Published January 20, 2021 · Recall initiated: January 4, 2021

Summary

FDA records drug Class II recall D-0227-2021, published January 20, 2021 and initiated January 4, 2021. Recalling firm: Nostrum Laboratories Inc; Status: Ongoing; Reported quantity: 6958 Bottles; Lot: MET200501 07/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Nostrum Laboratories Inc
Distributor
Nationwide
Lot
MET200501 07/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 tablets per bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120, NDC: 29033-056-01 recalled?

Yes. FDA published recall D-0227-2021 on January 20, 2021. Reported hazard: CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

What should I do if I have this product?

Voluntary: Firm initiated · Press Release